Labcorp Holdings Inc. to Release Q4 2025 Financial Results on February 17, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Should l Buy LH?
Source: PRnewswire
- Earnings Release Schedule: Labcorp will release its Q4 2025 financial results before the market opens on February 17, 2026, expected to provide key financial metrics and business performance insights for investors to assess market standing.
- Conference Call Details: The company will host a conference call and webcast at 9 a.m. ET on the same day to discuss the financial results, enhancing transparency and engaging with investors directly.
- Investor Relations Website: The earnings press release and accompanying financial information will be posted on Labcorp's Investor Relations website, ensuring timely access to the latest information for all stakeholders and improving information accessibility.
- Replay Availability: A replay of the webcast will be available approximately two hours after the live event and will remain accessible until February 4, 2027, ensuring that investors who cannot participate live can still obtain important information.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LH is 304.45 USD with a low forecast of 270.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 278.230
Low
270.00
Averages
304.45
High
325.00
Current: 278.230
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

- Earnings Release Schedule: Labcorp will release its Q4 2025 financial results before the market opens on February 17, 2026, expected to provide key financial metrics and business performance insights for investors to assess market standing.
- Conference Call Details: The company will host a conference call and webcast at 9 a.m. ET on the same day to discuss the financial results, enhancing transparency and engaging with investors directly.
- Investor Relations Website: The earnings press release and accompanying financial information will be posted on Labcorp's Investor Relations website, ensuring timely access to the latest information for all stakeholders and improving information accessibility.
- Replay Availability: A replay of the webcast will be available approximately two hours after the live event and will remain accessible until February 4, 2027, ensuring that investors who cannot participate live can still obtain important information.
See More
- UniFirst Dividend Announcement: UniFirst's Board of Directors declared a quarterly cash dividend of $0.365 per share, payable on March 27, 2026, reflecting the company's ongoing profitability and commitment to shareholder returns.
- Kaiser Aluminum Dividend Declaration: Kaiser Aluminum announced a cash dividend of $0.77 per share, payable on February 13, 2026, demonstrating the company's strong performance in maintaining stable cash flow and shareholder returns.
- Agree Realty Dividend Increase: Agree Realty declared a monthly cash dividend of $0.262, with an annualized amount rising to $3.144, a 3.6% increase from Q1 2025, showcasing the company's focus on shareholder value and confidence in profit growth.
- Labcorp Dividend Payment: Labcorp Holdings announced a cash dividend of $0.72 per share, payable on March 12, 2026, indicating its robust financial performance in the innovative laboratory services sector.
See More
- AI Investment Outlook: Goldman Sachs anticipates a deceleration in AI spending in 2026, while adoption rates increase, potentially causing rotations among major US tech stocks that create two-way risks for the aggregate index.
- EPAM Systems Performance: EPAM Systems has seen strong stock performance since raising its full-year revenue and earnings outlook in early November, with the CEO emphasizing the acceleration of transformation through AI investment and innovation to strengthen strategic positioning in AI-native enterprises.
- Affirm's AI Utilization: Affirm leverages AI to maximize merchant sales, with its AdaptAI providing personalized payment options that drive greater customer engagement, resulting in over a 30% stock price increase over the past year.
- Strong Market Performance: Bank stocks like Bank of America have outperformed the market over the past three months and hit an all-time high last week, indicating strong potential for AI-related stocks.
See More
- Quarterly Dividend Announcement: Labcorp Holdings has declared a quarterly dividend of $0.72 per share, consistent with previous distributions, indicating the company's stable cash flow and commitment to shareholder returns.
- Yield Information: The forward yield of this dividend stands at 1.13%, reflecting the company's attractiveness in the current market environment, which may draw in more income-focused investors.
- Shareholder Record Dates: The dividend is payable on March 12, with a record date of February 27 and an ex-dividend date also set for February 27, ensuring shareholders receive their payouts promptly.
- Future Outlook: Despite lowering the midpoint of its 2025 revenue guidance, Labcorp still targets an 8% revenue growth, demonstrating the company's ongoing efforts in restructuring and specialty expansion.
See More

- Dividend Declaration: Labcorp's Board of Directors has declared a cash dividend of $0.72 per share, payable on March 12, 2026, aimed at enhancing shareholder returns and attracting more investor interest.
- Record Date: The record date for this dividend is February 27, 2026, ensuring that investors holding shares by this date will benefit from the payout, thereby increasing the stock's appeal.
- Global Service Capability: Labcorp operates in nearly 100 countries with approximately 70,000 employees, supporting over 75% of new drugs and therapeutic products approved by the FDA in 2024, showcasing its leadership in the global healthcare market.
- Annual Testing Volume: The company performs over 700 million tests annually for patients worldwide, reflecting its robust laboratory capabilities and commitment to improving health, further solidifying its competitive advantage in the industry.
See More

- Dividend Announcement: Labcorp's Board of Directors has declared a cash dividend of $0.72 per share, payable on March 12, 2026, aimed at enhancing shareholder returns and boosting investor confidence.
- Record Date for Shareholders: The dividend will be distributed to shareholders of record as of the close of business on February 27, 2026, ensuring eligible shareholders receive their dividends and reflecting the company's commitment to its investors.
- Global Service Capability: Labcorp operates in nearly 100 countries with approximately 70,000 employees, supporting over 75% of new drugs and therapeutic products approved by the FDA in 2024, showcasing its leadership in the global healthcare sector.
- Annual Testing Volume: The company performs over 700 million tests annually for patients worldwide, demonstrating its robust laboratory capabilities and commitment to improving health, further solidifying its competitive position in the market.
See More







